Deep Vein Thrombosis-Pipeline Review 2021

Deep vein thrombosis (DVT) is termed as a medical condition which occurs when a blood clot forms in a vein situated deep inside human body. A blood clotting is a clump of blood which refers to a solid state. Deep vein blood clots mainly occurs in thigh or lower leg of patents, but they can also develop in other areas of the body. Other terms associated with this disorder may include thromboembolism, postphlebitic syndrome, and post-thrombotic syndrome.

There is increasing prevalence of DVT due to various factors. The major factor driving the growth is rising geriatric population across the globe, as aging is one of the risk factors for developing DVT. According to the Center of Disease Control and Prevention (CDC), it is projected that the around 900,000 people could be affected (1 to 2 per 1,000) annually in the U.S. alone. Along with the growing number of people associated with DVT, advancements are required for patients worldwide.

Pharmaceutical companies are focusing on launching drugs to treat deep vein thrombosis. Daiichi Sankyo Company, Limited declared that it has launched its oral anticoagulant Lixiana OD Tablets 15 mg, 30 mg and 60 mg (generic name: Edoxaban Tosilate Hydrate) in Japan. Lixianais is an oral anticoagulant that inhibits FXa (activated blood coagulation factor X) which is responsible for blood coagulation in blood vessels.

Approximately 40% of pipeline drugs for Deep Vein Thrombosis are in phase 3 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent deep vein thrombosis.

Report Description

The report on Deep Vein Thrombosis- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Deep Vein Thrombosis. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Deep Vein Thrombosis (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline